Publikationen

Petersen J, Wilke T, Mauss S, Heyne R, Herold C, Wiese M, Boeker K, Pichl T, Hueppe D. Real-life persistence and adherence in ETV treated chronic hepatitis b patients: results of a German prospective multicenter observational study.  J Hepatol Suppl. 2014;60(1):S423.

Böttger B, Wehling M, Bauersachs RM, Amann S, Schuchert A, Reinhold C, Kümpers P, Wilke T. Prevalence of renal insufficiency in hospitalised patients with venous thromboembolic events: A retrospective analysis based on 6,725 VTE patients. Thromb Res. 2014;134(5):1014–1019.

Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, Krabbe B. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2014;Epub ahead of print

Wilke T, Groth A, Fuchs A, Seitz L, Kienhöfer J, Lundershausen R, Maywald U. Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients. Diabetes Res Clin Pract. 2014;Epub ahead of print.

Müller S, Pfannkuche M, Breithardt G, Bauersachs R, Maywald U, Kohlmann T, Wilke T. The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Eur J Intern Med. 2014;25(3):247-254.

Böttger B, Wehling M, Bauersachs RM, Amann S, Wilke T. Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function. J Public Health. 2014;22(2):89-99.

Wilke T, Groth A, Müller S, Hastedt C, Fuchs A, Maywald U. Interruption/Bridging of VKA Treatment of Patients with Atrial Fibrillation: Analysis of Incidence and Clinical Outcomes Based on a German Claims Based Data Set. Value in Health. 2013;16(7):A517.

Böttger B, Wehling M, Bauersachs RM, Amann S, Wilke T. Initiale therapeutische Antikoagulation nach einem venösen thromboembolischen Ereignis von Patienten mit schwerer Nierenfunktionseinschränkung. German Medical Science. 2013;Epub

Charokopou M, Heeg B, Schoeman O, Müller S, Tempest M.J, Schlagmuller S.C,  Wilke T. A Comparison of Coverage and Reimbursement Decisions in Germany (AMNOG) and Scotland (SMC). Value in Health. 2013;16(7):A475–A476.

Heeg B, Schoeman O, Müller S, Wilke T. The Impact of AMNOG on Drug Reimbursement in Germany.Value in Health. 2013;16(7):A459.